trotz miserabler Zahlen für 2008, die gestern veröffentlich wurden,
(0,38 US Verlust pro Aktie) und vorallem nicht getroffen Analystenerwartungen zieht die Aktie weiter an.... hätte ich nicht gedacht...
Scheint doch noch unterbewertet zu sein...
gruß
massel
----------------------------------------------------------
Biolase Technology Q4 Loss Widens - Update
3/16/2009 5:05 PM ET
RELATED NEWS
Biolase Technology Q4 Loss Widens - Quick Facts
BIOLASE Technology Q4 & Year-End Earnings Conference Call At 4:30 PM
BIOLASE Technology names Frederick Capallo Interim CFO - Quick Facts
Biolase Technology CEO Jake St. Philip Resigns; David Mulder Named Successor - Update
BIOLASE CEO Jake Philip resigns; CFO Mulder named successor - Quick facts
(RTTNews) - Monday, Biolase Technology, Inc. (BLTI: News ), a medical technology company, reported a wider loss for the fourth quarter, as revenues declined from last year impacted by adverse macroeconomic factors.
The Irvine, California-based company posted a net loss $5.29 million or $0.22 per share for the quarter, wider than net loss of $1.15 million or $0.05 per share in the same period a year ago. Two analysts polled by Thomson Reuters expected the company to post a loss of $0.11 per share. Analysts' estimates typically exclude special items.
Net revenue for the quarter declined to $11.64 million from $20.84 million in the previous year. The Street anticipated revenues of $13.53 million.
David Mulder, Biolase chief executive officer said, "The top line result for Biolase as for most medical capital equipment suppliers has been impacted substantially by macroeconomic factors from late summer through today."
For fiscal 2008, the company reported a wider net loss of $9.1 million or $0.38 per share, compared to net loss of $7.3 million or $0.31 per share in the previous year. Full year revenues slipped to $64.62 million from $66.9 million last year. Analysts anticipated net loss of $0.27 per share on revenues of $66.53 million for the year.
BLTI closed Monday's trading up $0.14 or 17.95% at $0.92 on a volume of about 83 thousand shares.